Investigating how a virus affects lymphatic cells in AIDS patients
KSHV immortalization of human lymphatic endothelial cells
This study is looking at how a virus linked to Kaposi's Sarcoma affects certain cells in the body, which could help us find new ways to prevent or treat this cancer that often affects people with AIDS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11082534 on NIH RePORTER |
What this research studies
This research focuses on understanding how the Kaposi's Sarcoma-associated herpesvirus (KSHV) infects and transforms human lymphatic endothelial cells, which are crucial in the development of Kaposi's Sarcoma, a common cancer in AIDS patients. The researchers will study the early stages of KSHV infection and its ability to bypass cellular aging, leading to uncontrolled cell growth. By using primary neonatal lymphatic endothelial cells, the team aims to create a reliable model to explore the mechanisms of KSHV-induced cancer development. This could provide insights into potential therapeutic targets for preventing or treating cancers associated with AIDS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with AIDS, particularly those at risk for Kaposi's Sarcoma.
Not a fit: Patients who do not have AIDS or are not at risk for Kaposi's Sarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating Kaposi's Sarcoma and other cancers related to AIDS.
How similar studies have performed: Previous research has shown that understanding viral mechanisms in cancer development can lead to significant advancements in treatment, suggesting this approach has potential for success.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Lagunoff, Michael — University of Washington
- Study coordinator: Lagunoff, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.